Maxcyte (MXCT) Total Non-Current Liabilities (2020 - 2026)

Maxcyte (MXCT) has 7 years of Total Non-Current Liabilities data on file, last reported at $26.3 million in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $26.3 million, down 13.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $26.3 million (down 13.06% YoY), and the FY2025 annual result was $30.8 million, down 6.65% from the prior year.
• Total Non-Current Liabilities fell to $26.3 million in Q1 2026 per MXCT's latest filing, from $30.8 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $35.8 million in Q4 2023 and troughed at $26.3 million in Q1 2026.
• A 5-year average of $31.2 million and a median of $31.3 million in 2022 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2026: Total Non-Current Liabilities soared 144.74% in 2022, then dropped 13.06% in 2026.
• A 5-year view of Total Non-Current Liabilities shows it stood at $31.4 million in 2022, then advanced by 14.22% to $35.8 million in 2023, then slipped by 8.04% to $32.9 million in 2024, then slipped by 6.65% to $30.8 million in 2025, then fell by 14.4% to $26.3 million in 2026.
• Business Quant data shows MXCT's Total Non-Current Liabilities at $26.3 million in Q1 2026, $30.8 million in Q4 2025, and $33.0 million in Q3 2025.